Please login to the form below

Not currently logged in
Email:
Password:

Gilead sues Teva over patent for HIV drug

Biopharmaceutical company Gilead Sciences has filed a lawsuit in the US against Teva for infringement of its patents for Truvada

Biopharmaceutical company Gilead Sciences has filed a lawsuit in the US against Teva for infringement of its patents for Truvada, an antiretroviral agent for the treatment of HIV-1 in adults.

Teva has submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) requesting approval to manufacture and market a generic version of Truvada. Gilead has filed a lawsuit against the Israeli company as it claims it has two valid patents covering emtricitabine, a component of Truvada.

By filing a lawsuit, Gilead has temporarily put a stop to Teva's ANDA. The FDA is unable to approve the request for 30 months or until a court rules in favour of Teva.

Ten patents, all of which would need to be expired or invalidated before a generic version of the drug could be marketed, currently protect Truvada.

In November, PMLiVE reported that Cephalon and Eurand had filed a similar lawsuit against generic manufacturers Mylan and Barr relating to the muscle relaxant, Amrix.

As generic competition increases, we expect to see more manufacturers turning to the courts in a bid to defend their intellectual property.
 

15th December 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics